Τίτλος:
Pomalidomide plus low‐dose dexamethasone in relapsed/refractory multiple myeloma patients: Results of the real‐world “powerful” study
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The “POWERFUL” multicenter, retrospective, and prospective study investigated the effectiveness of pomalidomide plus low‐dose dexamethasone (POM/LoDex) therapy in relapsed/re-fractory multiple myeloma in routine care in Greece. Ninety‐nine eligible adult patients treated with POM/LoDex according to the approved label after having received ≥2 prior therapies, including lenalidomide and bortezomib, were consecutively enrolled between 16 November 2017 and 21 Feb-ruary 2019 in 18 hematology departments. Fifty patients (50.5%) started POM/LoDex as third‐line treatment. During the treatment period (median: 8.3 months; range: 0.3–47.6 months), the median POM dose was 4 mg/day, and 31.3% of the patients received additional antimyeloma agents. The overall response rate was 32.3%. During a median follow‐up period of 13.8 months (Kaplan–Meier estimate), the median progression‐free survival (PFS) was 10.5 months (95% CI: 7.4–14.4). The PFS was not significantly different between patients receiving POM/LoDex in the third versus later line of therapy, nor between patients receiving concomitant antimyeloma therapy versus POM/LoDEx doublet. During the prospective safety data collection period (median: 7.6 months) among patients with prospective follow‐up (N = 75), POM‐related adverse event incidence rate was 42.7% (serious: 18.7%; grade ≥ 3 hematological POM‐related adverse events: 8.0%). Only neutropenia (13.3%) was reported at a frequency ≥10%. In conclusion, in this real‐world study, POM/LoDex displayed a long PFS with no new safety signals emerging. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Συγγραφείς:
Terpos, E.
Repousis, P.
Lalayanni, C.
Hatjiharissi, E.
Assimakopoulou, T.
Vassilopoulos, G.
Pouli, A.
Spanoudakis, E.
Michalis, E.
Pangalis, G.
Ntanasis‐stathopoulos, I.
Poziopoulos, C.
Kyrtsonis, M.-C.
Pappa, V.
Symeonidis, A.
Georgopoulos, C.
Zikos, P.M.
Gavriatopoulou, M.
Papadaki, H.A.
Dadakaridou, M.
Karvounis‐marolachakis, K.
Katodritou, E.
Περιοδικό:
Journal of Clinical Medicine Research
Λέξεις-κλειδιά:
allopurinol; antianemic agent; antibiotic agent; anticoagulant agent; antifungal agent; antivirus agent; bendamustine; bortezomib; carfilzomib; cisplatin; creatinine; cyclophosphamide; daratumumab; dexamethasone; doxorubicin; etoposide; febuxostat; filgrastim; immunoglobulin A; immunoglobulin G; ixazomib; lactate dehydrogenase; lenalidomide; melphalan; panobinostat; pomalidomide; selinexor; steroid; sulfamethoxazole; thalidomide; trimethoprim; vinblastine; vincristine, acute kidney failure; adverse drug reaction; aged; anemia; Article; autologous stem cell transplantation; backache; cancer combination chemotherapy; cancer patient; cancer recurrence; clinical evaluation; cohort analysis; controlled study; deep vein thrombosis; diarrhea; disease exacerbation; diseases; drug dose reduction; drug efficacy; drug safety; drug utilization; drug withdrawal; fatality; female; follow up; human; incidence; infection; lactate dehydrogenase blood level; low drug dose; major clinical study; male; medical record review; minimal residual disease; multiple cycle treatment; multiple myeloma; neutropenia; neutrophil count; observational study; overall response rate; platelet count; progression free survival; prospective study; recommended drug dose; relapse; retrospective study; stomach hemorrhage; thrombocytopenia; thrombosis prevention; treatment duration; treatment indication; treatment response; treatment response time; urinary tract infection
